TP53 and glioblastoma: Studies on GBM cells couple signaling from the EGFR receptor to reduced sensitivity to chemotherapeutic agents that, like TMZ, have alkylating activity [41,42], while p53 inactivation in GBM cells results in increased TMZ sensitivity [43,44].